| FDA readies for rivaroxaban stroke/AF review - TheHeart.Org |
|
|
TheHeart.Org Adelphi, MD - The FDA has announced that its Cardiovascular and Renal Drugs Advisory Committee will meet September 8, 2011 to review the new drug application (NDA) for rivaroxaban (Xarelto, Bayer/Johnson & Johnson) for the prevention of stroke and |